<i>In vivo</i> efficacy of sEphB4-HSA combined with Bevacizumab.
Xiuqing Li
Wesley W. Choi
Rui Yan
Haiyang Yu
Valery Krasnoperov
S. Ram Kumar
Anne Schuckman
David J. Klumpp
Chong-Xian Pan
David Quinn
Inderbir S. Gill
Parkash S. Gill
Ren Liu
10.1371/journal.pone.0105326.g003
https://plos.figshare.com/articles/figure/_In_vivo_efficacy_of_sEphB4_HSA_combined_with_Bevacizumab_/1149461
<p>A, 5637 tumors were treated with sEphB4-HSA alone (20 mg/kg, 3 times a week), Bevacizamab alone (20 mg/kg, 3 times a week), or sEphB4-HSA combined with Bevacizamab. PBS was used as control. Data are presented as mean ± standard deviation. Student <i>t</i>-test (2 tails, unpaired) was used to calculate P value: *, P<0.05; **, P<0.01. B, tumors harvested from the xenograft study were lysed for EphB4 immunoprecipitation, followed by immunoblotting using EphB4 and phopho-tyrosine antibodies. sEphB4-HSA treatment significantly reduced EphB4 tyrosine phosphorylation <i>in vivo</i>.</p>
2014-08-22 03:36:13
Transitional Cell Carcinoma
EphB 4 expression
bladder tumor xenograft
survival factor
tumor cell lines
24 cases
EphB 4 signal strength
EphB 2
EphB 4
EphB 4 Receptor Kinases
cis
tyrosine kinase activity
TCC specimens show loss